GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know

GlaxoSmithKline (NYSE: GSK) and Vir Biotechnology (NASDAQ: VIR) recently reported results from a confirmatory study evaluating antibody therapy sotrovimab in treating non-hospitalized COVID-19 patients. In this Motley Fool Live video recorded on June 23, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss what investors should know about these results.

Continue reading

Source Fool.com